JP2016128513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016128513A5 JP2016128513A5 JP2016068623A JP2016068623A JP2016128513A5 JP 2016128513 A5 JP2016128513 A5 JP 2016128513A5 JP 2016068623 A JP2016068623 A JP 2016068623A JP 2016068623 A JP2016068623 A JP 2016068623A JP 2016128513 A5 JP2016128513 A5 JP 2016128513A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- positions
- use according
- hbv
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700721 Hepatitis B virus Species 0.000 claims 103
- 125000003275 alpha amino acid group Chemical group 0.000 claims 87
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 63
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 63
- 238000009169 immunotherapy Methods 0.000 claims 63
- 108020001507 fusion proteins Proteins 0.000 claims 60
- 102000037865 fusion proteins Human genes 0.000 claims 60
- 239000000427 antigen Substances 0.000 claims 56
- 102000036639 antigens Human genes 0.000 claims 56
- 108091007433 antigens Proteins 0.000 claims 56
- 230000000840 anti-viral effect Effects 0.000 claims 33
- 230000001024 immunotherapeutic effect Effects 0.000 claims 23
- 101710132601 Capsid protein Proteins 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 208000015181 infectious disease Diseases 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 9
- 238000004519 manufacturing process Methods 0.000 claims 9
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims 8
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 210000005253 yeast cell Anatomy 0.000 claims 3
- 206010067125 Liver injury Diseases 0.000 claims 2
- 231100000234 hepatic damage Toxicity 0.000 claims 2
- 230000008818 liver damage Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161442204P | 2011-02-12 | 2011-02-12 | |
| US61/442,204 | 2011-02-12 | ||
| US201161496945P | 2011-06-14 | 2011-06-14 | |
| US61/496,945 | 2011-06-14 | ||
| US201161507361P | 2011-07-13 | 2011-07-13 | |
| US61/507,361 | 2011-07-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015025534A Division JP5911983B2 (ja) | 2011-02-12 | 2015-02-12 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017043689A Division JP2017105834A (ja) | 2011-02-12 | 2017-03-08 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016128513A JP2016128513A (ja) | 2016-07-14 |
| JP2016128513A5 true JP2016128513A5 (enExample) | 2016-12-22 |
| JP6109989B2 JP6109989B2 (ja) | 2017-04-05 |
Family
ID=46638950
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553534A Active JP5745102B2 (ja) | 2011-02-12 | 2012-02-09 | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 |
| JP2015025534A Active JP5911983B2 (ja) | 2011-02-12 | 2015-02-12 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
| JP2016068623A Active JP6109989B2 (ja) | 2011-02-12 | 2016-03-30 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
| JP2017043689A Pending JP2017105834A (ja) | 2011-02-12 | 2017-03-08 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553534A Active JP5745102B2 (ja) | 2011-02-12 | 2012-02-09 | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 |
| JP2015025534A Active JP5911983B2 (ja) | 2011-02-12 | 2015-02-12 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017043689A Pending JP2017105834A (ja) | 2011-02-12 | 2017-03-08 | 慢性ｂ型肝炎感染症のための酵母系治療薬 |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US8877205B2 (enExample) |
| EP (2) | EP2672991B1 (enExample) |
| JP (4) | JP5745102B2 (enExample) |
| KR (1) | KR102026840B1 (enExample) |
| CN (1) | CN103476426B (enExample) |
| AP (1) | AP2013007110A0 (enExample) |
| AU (2) | AU2012214394B2 (enExample) |
| BR (1) | BR112013020425A2 (enExample) |
| CA (1) | CA2827150C (enExample) |
| CL (1) | CL2013002334A1 (enExample) |
| CO (1) | CO6791572A2 (enExample) |
| CR (1) | CR20130424A (enExample) |
| EA (1) | EA028659B1 (enExample) |
| EC (1) | ECSP13012862A (enExample) |
| ES (1) | ES2643389T3 (enExample) |
| HK (1) | HK1248120A1 (enExample) |
| IL (1) | IL227900B (enExample) |
| MA (1) | MA34956B1 (enExample) |
| PE (1) | PE20140844A1 (enExample) |
| PH (1) | PH12013501683A1 (enExample) |
| SG (1) | SG192285A1 (enExample) |
| TW (1) | TWI504608B (enExample) |
| UA (1) | UA112859C2 (enExample) |
| WO (1) | WO2012109404A1 (enExample) |
| ZA (1) | ZA201306481B (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| US9238679B2 (en) * | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
| WO2012109668A1 (en) | 2011-02-11 | 2012-08-16 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same |
| AU2012214394B2 (en) | 2011-02-12 | 2016-08-11 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis B infection |
| EP3238731B1 (en) | 2011-03-17 | 2021-02-17 | Globeimmune, Inc. | Yeast-brachyury immunotherapeutic compositions |
| WO2012174220A1 (en) | 2011-06-14 | 2012-12-20 | Globeimmune, Inc. | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection |
| KR102049928B1 (ko) | 2011-08-17 | 2019-11-28 | 글로브이뮨 | 효모-muc1 면역요법 조성물 및 그 용도 |
| AU2013281221B2 (en) | 2012-06-26 | 2018-05-17 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| PL2917231T3 (pl) | 2012-11-12 | 2019-08-30 | Ruprecht-Karls-Universität Heidelberg | Lipopeptydy do stosowania w leczeniu chorób wątroby i chorób sercowo-naczyniowych |
| SG10201707608QA (en) | 2013-03-19 | 2017-10-30 | Globeimmune Inc | Yeast-based immunotherapy for chordoma |
| TWI626948B (zh) | 2013-03-26 | 2018-06-21 | 環球免疫公司 | 治療或預防人類免疫缺乏病毒感染之組合物及方法 |
| US10226522B2 (en) | 2013-08-30 | 2019-03-12 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of tuberculosis |
| WO2015157639A1 (en) | 2014-04-11 | 2015-10-15 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
| US10507240B2 (en) | 2014-11-28 | 2019-12-17 | Celltrion, Inc. | Epitope of hepatitis B virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis B virus |
| JP2018502922A (ja) | 2015-01-09 | 2018-02-01 | イーチュービクス コーポレイション | エボラウイルスワクチン接種のための方法および組成物 |
| AU2016216673B2 (en) | 2015-03-04 | 2017-02-02 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| AU2016303525B2 (en) | 2015-08-03 | 2021-01-21 | Globeimmune, Inc. | Modified yeast-Brachyury immunotherapeutic compositions |
| JP2018525412A (ja) | 2015-08-26 | 2018-09-06 | ギリアード サイエンシーズ， インコーポレイテッド | 重水素化トール様受容体調節因子 |
| EP4177348A1 (en) * | 2015-11-04 | 2023-05-10 | Hookipa Biotech GmbH | Vaccines against hepatitis b virus |
| CA3002508A1 (en) * | 2016-01-12 | 2017-07-20 | Ulrike Protzer | Means and methods for treating hbv |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| EP3276006A1 (en) * | 2016-07-27 | 2018-01-31 | Theravectys | Lentiviral vectors for expression of hepatitis b virus (hbv) antigens |
| EP3507288B1 (en) | 2016-09-02 | 2020-08-26 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CN106421774B (zh) * | 2016-09-08 | 2019-05-28 | 中国科学院生物物理研究所 | PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途 |
| US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
| TWI820984B (zh) | 2017-01-31 | 2023-11-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| GB201705765D0 (en) | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| JP6613399B2 (ja) * | 2017-06-05 | 2019-12-04 | 株式会社ビークル | Ｈｂｖに対する免疫応答を生じさせるために用いられるウイルス様粒子 |
| JP6934562B2 (ja) | 2017-08-22 | 2021-09-15 | ギリアード サイエンシーズ， インコーポレイテッド | 治療用複素環式化合物 |
| MX2020006480A (es) * | 2017-12-19 | 2020-09-22 | Janssen Sciences Ireland Unlimited Co | Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas. |
| EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| CA3085492A1 (en) * | 2017-12-19 | 2019-06-27 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
| TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| EP3762022A4 (en) | 2018-03-06 | 2022-06-15 | Precigen, Inc. | HUMAN PAPILLOMAVIRUS VACCINES AND USES THEREOF |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| CN112543640B (zh) | 2018-05-15 | 2025-02-14 | 全球免疫公司 | 用于诱导细胞免疫应答的重组酵母裂解物 |
| CA3103987C (en) | 2018-07-06 | 2023-08-01 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| CN112384283B (zh) | 2018-07-06 | 2023-08-15 | 吉利德科学公司 | 治疗性的杂环化合物 |
| MX2021000100A (es) | 2018-07-13 | 2021-03-25 | Gilead Sciences Inc | Inhibidores de muerte programada-1 (pd-1)/ ligando de muerte programada 1 (pd-l1). |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| HRP20240541T1 (hr) | 2018-10-31 | 2024-07-05 | Gilead Sciences, Inc. | Supstituirani spojevi 6-azabenzimidazola kao inhibitori hpk1 |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| WO2020254876A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Virus-like particle delivery of hepatitis b virus (hbv) vaccines |
| WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| KR102776925B1 (ko) | 2019-06-25 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Flt3l-fc 융합 단백질 및 사용 방법 |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| JP7635208B2 (ja) | 2019-08-29 | 2025-02-25 | ブイアイアール バイオテクノロジー インコーポレイテッド | Ｂ型肝炎ウイルスワクチン |
| CN114514427A (zh) * | 2019-09-27 | 2022-05-17 | 富士瑞必欧株式会社 | 乙型肝炎病毒核心相关抗原的免疫测定和用于其的试剂盒 |
| FI4037708T3 (fi) | 2019-09-30 | 2024-10-31 | Gilead Sciences Inc | Hbv-rokotteita ja menetelmiä, hbv:n hoitamiseksi |
| EP4567109A3 (en) | 2019-12-06 | 2025-09-17 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| KR20220163354A (ko) | 2020-01-09 | 2022-12-09 | 비리온 테라퓨틱스, 엘엘씨 | 헤르페스 바이러스 당단백질 d와 융합된 간염 b 바이러스 항원들을 인코딩하는 아데노바이러스 벡터들 및 이를 이용하는 방법 |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| WO2022006146A1 (en) * | 2020-06-29 | 2022-01-06 | The Trustees Of Columbia University In The City Of New York | Yeast-based vaccines |
| EP4192474B1 (en) | 2020-08-07 | 2025-09-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| TW202310852A (zh) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合 |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| US11999733B2 (en) | 2021-06-23 | 2024-06-04 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2023085956A1 (en) * | 2021-11-09 | 2023-05-19 | Avalia Immunotherapies Limited | Novel therapeutic vaccines |
| WO2024220982A1 (en) * | 2023-04-21 | 2024-10-24 | The Wistar Institute Of Anatomy And Biology | Compositions comprising aptamers and methods of modulating the immune response using the same |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
| US5164485A (en) | 1985-08-20 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Modified hepatitis B virus surface antigen P31 and production thereof |
| US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
| US6306625B1 (en) * | 1988-12-30 | 2001-10-23 | Smithkline Beecham Biologicals, Sa | Method for obtaining expression of mixed polypeptide particles in yeast |
| IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
| US6607727B1 (en) * | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
| WO1994012617A1 (en) * | 1992-11-25 | 1994-06-09 | International Biotechnology Laboratories, Inc. | Hepatitis b virus vaccines |
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| JP3713900B2 (ja) | 1996-07-19 | 2005-11-09 | ソニー株式会社 | 負極材料及びこれを用いた非水電解液二次電池 |
| CA2320488C (en) * | 1998-02-12 | 2007-03-06 | Immune Complex, Corporation | Strategically modified hepatitis b core proteins and their derivatives |
| HK1048492A1 (zh) * | 1999-12-03 | 2003-04-04 | Innogenetics N.V. | 新的hbv序列 |
| GB0216074D0 (en) * | 2002-07-11 | 2002-08-21 | Weatherford Lamb | Improving collapse resistance of tubing |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| US8153414B2 (en) | 2000-04-06 | 2012-04-10 | Allertein Therapeutics, Llc | Microbial delivery system |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| CN1171636C (zh) * | 2001-06-06 | 2004-10-20 | 中国人民解放军第二军医大学 | 一种乙型肝炎dna疫苗 |
| US8029803B2 (en) * | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| CN102370974B (zh) | 2002-12-16 | 2014-09-17 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
| US8343502B2 (en) | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| EP1609107A4 (en) * | 2003-03-28 | 2006-08-30 | Idm Pharma Inc | METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS |
| DE10339927A1 (de) | 2003-08-29 | 2005-03-24 | Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH | Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen |
| KR20070068460A (ko) | 2004-10-18 | 2007-06-29 | 글로브이뮨 | 만성 ｃ형 간염에 대한 효모계 치료 |
| EP2371381A3 (en) | 2005-07-11 | 2012-07-18 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| MX2008009929A (es) | 2006-02-02 | 2008-10-01 | Globeimmune Inc | Vacuna a base de levadura para inducir una respuesta inmune. |
| KR20090008290A (ko) | 2006-03-27 | 2009-01-21 | 글로브이뮨 | Ｒａｓ 돌연변이와 그에 관련된 조성물 및 방법 |
| KR100836745B1 (ko) * | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| CN101687030B (zh) | 2007-02-02 | 2014-07-02 | 环球免疫公司 | 用于生产基于酵母的疫苗的方法 |
| CN101036784B (zh) * | 2007-03-09 | 2010-11-10 | 中国人民解放军第二军医大学 | 一种乙型肝炎治疗性细胞毒性t细胞表位疫苗及其制备方法 |
| CN101730542A (zh) | 2007-03-19 | 2010-06-09 | 环球免疫公司 | 用于靶向消除癌症靶向疗法的突变逃逸的组合物和方法 |
| EP2331125A4 (en) | 2008-09-19 | 2013-03-27 | Globeimmune Inc | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| AU2010236206B2 (en) | 2009-04-17 | 2016-10-20 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| CA2774326C (en) | 2009-09-14 | 2023-11-07 | Donald Bellgrau | Modulation of yeast-based immunotherapy products and responses |
| JP2013522302A (ja) * | 2010-03-14 | 2013-06-13 | グローブイミューン，インコーポレイテッド | 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療 |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| AU2012214394B2 (en) | 2011-02-12 | 2016-08-11 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis B infection |
| EP3238731B1 (en) | 2011-03-17 | 2021-02-17 | Globeimmune, Inc. | Yeast-brachyury immunotherapeutic compositions |
| WO2012174220A1 (en) | 2011-06-14 | 2012-12-20 | Globeimmune, Inc. | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection |
| KR102049928B1 (ko) | 2011-08-17 | 2019-11-28 | 글로브이뮨 | 효모-muc1 면역요법 조성물 및 그 용도 |
-
2012
- 2012-02-09 AU AU2012214394A patent/AU2012214394B2/en active Active
- 2012-02-09 JP JP2013553534A patent/JP5745102B2/ja active Active
- 2012-02-09 CN CN201280018222.5A patent/CN103476426B/zh active Active
- 2012-02-09 KR KR1020137024018A patent/KR102026840B1/ko active Active
- 2012-02-09 WO PCT/US2012/024409 patent/WO2012109404A1/en not_active Ceased
- 2012-02-09 US US13/984,888 patent/US8877205B2/en active Active
- 2012-02-09 PE PE2013001865A patent/PE20140844A1/es not_active Application Discontinuation
- 2012-02-09 ES ES12744328.1T patent/ES2643389T3/es active Active
- 2012-02-09 CA CA2827150A patent/CA2827150C/en active Active
- 2012-02-09 PH PH1/2013/501683A patent/PH12013501683A1/en unknown
- 2012-02-09 EP EP12744328.1A patent/EP2672991B1/en active Active
- 2012-02-09 EA EA201391170A patent/EA028659B1/ru not_active IP Right Cessation
- 2012-02-09 SG SG2013060777A patent/SG192285A1/en unknown
- 2012-02-09 MA MA36222A patent/MA34956B1/fr unknown
- 2012-02-09 EP EP17175311.4A patent/EP3266464A3/en not_active Withdrawn
- 2012-02-09 BR BR112013020425A patent/BR112013020425A2/pt not_active IP Right Cessation
- 2012-02-09 AP AP2013007110A patent/AP2013007110A0/xx unknown
- 2012-02-10 TW TW101104436A patent/TWI504608B/zh active
- 2012-09-02 UA UAA201310911A patent/UA112859C2/uk unknown
-
2013
- 2013-03-13 US US13/798,837 patent/US8722054B2/en active Active
- 2013-08-12 CL CL2013002334A patent/CL2013002334A1/es unknown
- 2013-08-28 ZA ZA2013/06481A patent/ZA201306481B/en unknown
- 2013-08-30 EC ECSP13012862 patent/ECSP13012862A/es unknown
- 2013-08-31 CR CR20130424A patent/CR20130424A/es unknown
- 2013-09-12 CO CO13216900A patent/CO6791572A2/es unknown
- 2013-09-29 IL IL227900A patent/IL227900B/en active IP Right Grant
-
2014
- 2014-02-19 US US14/184,481 patent/US8961988B2/en active Active
- 2014-09-23 US US14/494,235 patent/US9290547B2/en active Active
-
2015
- 2015-01-07 US US14/591,592 patent/US9428556B2/en active Active
- 2015-02-12 JP JP2015025534A patent/JP5911983B2/ja active Active
-
2016
- 2016-03-30 JP JP2016068623A patent/JP6109989B2/ja active Active
- 2016-07-18 US US15/212,930 patent/US9943591B2/en active Active
- 2016-11-10 AU AU2016256751A patent/AU2016256751B2/en active Active
-
2017
- 2017-03-08 JP JP2017043689A patent/JP2017105834A/ja active Pending
-
2018
- 2018-03-01 US US15/909,112 patent/US10441650B2/en active Active
- 2018-06-13 HK HK18107680.0A patent/HK1248120A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016128513A5 (enExample) | ||
| JP2015096557A5 (enExample) | ||
| Spyrou et al. | Hepatitis B: current status of therapy and future therapies | |
| Kim et al. | Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus | |
| Liang et al. | Present and future therapies of hepatitis B: from discovery to cure | |
| Paladini et al. | The worldwide impact of vaccination on the control and protection of viral hepatitis B | |
| CN110612118B (zh) | 用于引起针对hbv的免疫应答的病毒样粒子 | |
| Li et al. | Research progress of therapeutic vaccines for treating chronic hepatitis B | |
| RU2749730C1 (ru) | Бисдиазабицикло-соединение для лечения и/или профилактики заболеваний или расстройств, связанных с вирусом гепатита | |
| JP2014507144A5 (ja) | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 | |
| JP2014527404A5 (enExample) | ||
| JP2014523878A5 (enExample) | ||
| WO2008103380A3 (en) | Hepatitis b virus compositions and methods of use | |
| JP2017515508A5 (enExample) | ||
| Yoshida et al. | Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical study | |
| Karimkhanilouyi et al. | Nucleic acid vaccines for hepatitis B and C virus | |
| Jilg | Novel hepatitis B vaccines | |
| Tang et al. | Advances in new antivirals for chronic hepatitis B | |
| EP3437654B1 (en) | Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus | |
| Pentón-Arias et al. | Cuban prophylactic and therapeutic vaccines for controlling hepatitis B | |
| CN101717433A (zh) | 一种多肽免疫原及其制备方法和应用 | |
| JP2014534262A5 (enExample) | ||
| CN106421774A (zh) | PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途 | |
| Wen et al. | Vaccine therapies for chronic hepatitis B: can we go further? | |
| Hong et al. | Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice |